Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Metastatic Refractory Soft Tissue Sarcoma
NCT01755195Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2013
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 86 months and 6 Month Progression Free Survival Rate. Started Jan 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01755195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01755195.